Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Press Release : Affimed to Report Full Year 2020 Financial Results & Corporate Update on April 15, 2021

04/08/2021 | 06:30am EDT
 
   Heidelberg, Germany, April 8, 2021 -- Affimed N.V. (Nasdaq: AFMD), a 
clinical-stage immuno-oncology company committed to giving patients back 
their innate ability to fight cancer, announced today that it will 
release full year 2020 results and corporate update on Thursday, April 
15, 2021. The Company will host a conference call at 8:30 a.m. Eastern 
Daylight Time. 
 
   The conference call will be available via phone and webcast. To access 
the call, please dial +1-646-741-3167 for U.S. callers, or +44 (0) 2071 
928338 for international callers, and reference conference ID 4271307 
approximately 15 minutes prior to the call. 
 
   To access the live audio webcast of the conference call please visit the 
"Investors" section of the company's website at 
https://www.globenewswire.com/Tracker?data=XTsxj1F5YwvjSkHxe0nDC2Gqb0cr8F8GrKD2y9-RlLAz1FuUu97G9m0oYgAZ9oaTm6aexW7ERBzslwWrA6XISLKVEurNy1JmWzOhvdl50GRdJOGzU6xgx2D4NHbI0Ol91Z9DkIplj6AAtg6t0KR2QPfvOXG5K7LBlmfFpUFIkYU= 
https://www.affimed.com/investors/webcasts_cp/. A replay of the call 
will be archived on the Affimed website for 30 days after the call. 
 
   About Affimed N.V. 
 
   Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company 
committed to give patients back their innate ability to fight cancer by 
actualizing the untapped potential of the innate immune system. The 
company's proprietary ROCK(R) platform enables a tumor-targeted approach 
to recognize and kill a range of hematologic and solid tumors, enabling 
a broad pipeline of wholly-owned and partnered single agent and 
combination therapy programs. The ROCK(R) platform predictably generates 
customized innate cell engager (ICE(R)) molecules, which use patients' 
immune cells to destroy tumor cells. This innovative approach enabled 
Affimed to become the first company with a clinical-stage ICE(R). 
Headquartered in Heidelberg, Germany, with offices in New York, NY, 
Affimed is led by an experienced team of biotechnology and 
pharmaceutical leaders united by a bold vision to stop cancer from ever 
derailing patients' lives. For more about the company's people, pipeline 
and partners, please visit: 
https://www.globenewswire.com/Tracker?data=p-Z-E1BtgOS1vCiZYBcWfVg6x6G8XaHbMhoRhuwziV5V9mBuDsFfSX7dE13O7tTl0NCorjr-W5dqs2B74s8PEA== 
www.affimed.com. 
 
   Investor Relations Contact 
 
   Alex Fudukidis 
 
   Head of Investor Relations 
 
   E-Mail: 
https://www.globenewswire.com/Tracker?data=DYem8437D22U68ZIZp00yU2uUoB28Gisk3qRVdiIiX_xiuA6yg22WEXVHZbeUjE0WSImkp7dgIXOSlaz5TPTVznboDsMW5PK3oVzhbElZFo= 
a.fudukidis@affimed.com 
 
   Tel: +1 (917) 436-8102 
 
 
 
 

(END) Dow Jones Newswires

April 08, 2021 06:30 ET (10:30 GMT)

All news about AFFIMED N.V.
04/16XOMA  : Royalty Portfolio Grows with Addition of Three Royalty Assets
AQ
04/15XOMA  : Adds Three Royalty Assets From Affimed
MT
04/15AFFIMED N  : Reports FY20 Loss; Revenue Declines
MT
04/15Affimed Reports 2020 Financial Results and Highlights Recent Operational Pro..
GL
04/15PRESS RELEASE  : Affimed Reports 2020 Financial -3-
DJ
04/15PRESS RELEASE  : Affimed Reports 2020 Financial -2-
DJ
04/15PRESS RELEASE  : Affimed Reports 2020 Financial Results and Highlights Recent Op..
DJ
04/13AFFIMED N  : Fourth Quarter 2020 Financial Results and Corporate Update Conferen..
PU
04/13CONFERENCE CALL : AACR, data presented on cbNK cells pre-complexed with AFM13
PU
04/12AFFIMED N  : BMO Capital Adjusts Affimed's Price Target to $15 From $12, Keeps O..
MT
More news
Financials
Sales 2021 32,8 M 39,3 M 39,3 M
Net income 2021 -50,9 M -61,0 M -61,0 M
Net cash 2021 194 M 232 M 232 M
P/E ratio 2021 -17,1x
Yield 2021 -
Capitalization 944 M 1 131 M 1 131 M
EV / Sales 2021 22,9x
EV / Sales 2022 12,5x
Nbr of Employees 137
Free-Float 83,5%
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 12,81 €
Last Close Price 7,94 €
Spread / Highest target 89,5%
Spread / Average Target 61,4%
Spread / Lowest Target 47,4%
EPS Revisions
Managers and Directors
NameTitle
Adolf Hoess Chief Executive Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
AFFIMED N.V.63.40%1 112
GILEAD SCIENCES, INC.12.89%82 808
VERTEX PHARMACEUTICALS INCORPORATED-7.17%57 225
REGENERON PHARMACEUTICALS, INC.2.39%51 514
WUXI APPTEC CO., LTD.-0.05%50 406
BIONTECH SE85.89%33 987